Emerging Cellular Therapies for Cancer

被引：261

作者：

Guedan, Sonia ^{[1
,2
]}

Ruella, Marco ^{[2
,3
,4
]}

June, Carl H. ^{[2
,3
,4
,5
]}

机构：

[1] Hosp Clin Barcelona, Inst Invest Biomed August Pi & Sunyer IDIBAPS, Dept Hematol, Barcelona 08036, Spain

[2] Univ Penn, Perelman Sch Med, Ctr Cellular Immunotherapies, Philadelphia, PA 19104 USA

[3] Univ Penn, Perelman Sch Med, Dept Med, Div Hematol & Oncol, Philadelphia, PA 19104 USA

[4] Univ Penn, Parker Inst Cellular Immunotherapy, Philadelphia, PA 19104 USA

[5] Univ Penn, Perelman Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA

来源：

ANNUAL REVIEW OF IMMUNOLOGY, VOL 37, 2019 | 2019年 / 37卷

关键词：

chimeric antigen receptor; CAR-T cell; adoptive cell transfer; immune-oncology; leukemia; synthetic biology; CHIMERIC-ANTIGEN-RECEPTOR; CAR-T-CELLS; TUMOR-INFILTRATING LYMPHOCYTES; ACUTE MYELOID-LEUKEMIA; FIBROBLAST ACTIVATION PROTEIN; ACUTE LYMPHOBLASTIC-LEUKEMIA; CYTOKINE RELEASE SYNDROME; TERM-FOLLOW-UP; B-CELL; ANTITUMOR-ACTIVITY;

D O I：

10.1146/annurev-immunol-042718-041407

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Genetically engineered T cells are powerful new medicines, offering hope for curative responses in patients with cancer. Chimeric antigen receptor (CAR) T cells were recently approved by the US Food and Drug Administration and are poised to enter the practice of medicine for leukemia and lymphoma, demonstrating that engineered immune cells can serve as a powerful new class of cancer therapeutics. The emergence of synthetic biology approaches for cellular engineering provides a broadly expanded set of tools for programming immune cells for enhanced function. Advances in T cell engineering, genetic editing, the selection of optimal lymphocytes, and cell manufacturing have the potential to broaden T cell-based therapies and foster new applications beyond oncology, in infectious diseases, organ transplantation, and autoimmunity.

引用

页码：145 / 171

页数：27

共 198 条

[1] Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity [J].

Adusumilli, Prasad S. ;

Cherkassky, Leonid ;

Villena-Vargas, Jonathan ;

Colovos, Christos ;

Servais, Elliot ;

Plotkin, Jason ;

Jones, David R. ;

Sadelain, Michel .

SCIENCE TRANSLATIONAL MEDICINE, 2014, 6 (261)

[2] Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma [J].

Ahmed, Nabil ;

Brawley, Vita S. ;

Hegde, Meenakshi ;

Robertson, Catherine ;

Ghazi, Alexia ;

Gerken, Claudia ;

Liu, Enli ;

Dakhova, Olga ;

Ashoori, Aidin ;

Corder, Amanda ;

Gray, Tara ;

Wu, Meng-Fen ;

Liu, Hao ;

Hicks, John ;

Rainusso, Nino ;

Dotti, Gianpietro ;

Mei, Zhuyong ;

Grilley, Bambi ;

Gee, Adrian ;

Rooney, Cliona M. ;

Brenner, Malcolm K. ;

Heslop, Helen E. ;

Wels, Winfried S. ;

Wang, Lisa L. ;

Anderson, Peter ;

Gottschalk, Stephen .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15) :1688-+

[3] Oncolytic Adenoviral Delivery of an EGFR-Targeting T-cell Engager Improves Antitumor Efficacy [J].

Alberto Fajardo, Carlos ;

Guedan, Sonia ;

Alfonso Rojas, Luis ;

Moreno, Rafael ;

Arias-Badia, Marcel ;

de Sostoa, Jana ;

June, Carl H. ;

Alemany, Ramon .

CANCER RESEARCH, 2017, 77 (08) :2052-2063

[4]

[Anonymous], 2015, BLOOD

[5]

[Anonymous], 2014, BLOOD, DOI DOI 10.1182/BLOOD.V124.21.120.120

[6] Kinetics of Tumor Destruction by Chimeric Antigen Receptor-modified T Cells [J].

Anurathapan, Usanarat ;

Chan, Robert C. ;

Hindi, Hakeem F. ;

Mucharla, Roopa ;

Bajgain, Pradip ;

Hayes, Brendan C. ;

Fisher, William E. ;

Heslop, Helen E. ;

Rooney, Cliona M. ;

Brenner, Malcolm K. ;

Leen, Ann M. ;

Vera, Juan F. .

MOLECULAR THERAPY, 2014, 22 (03) :623-633

[7] Myeloid-derived suppressor cell impact on endogenous and adoptively transferred T cells [J].

Arina, Ainhoa ;

Bronte, Vincenzo .

CURRENT OPINION IN IMMUNOLOGY, 2015, 33 :120-125

[8] Regimen-Specific Effects of RNA-Modified Chimeric Antigen Receptor T Cells in Mice with Advanced Leukemia [J].

Barrett, David M. ;

Liu, Xiaojun ;

Jiang, Shuguang ;

June, Carl H. ;

Grupp, Stephan A. ;

Zhao, Yangbing .

HUMAN GENE THERAPY, 2013, 24 (08) :717-727

[9] Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial [J].

Beatty, Gregory L. ;

O'Hara, Mark H. ;

Lacey, Simon F. ;

Torigian, Drew A. ;

Nazimuddin, Farzana ;

Chen, Fang ;

Kulikovskaya, Irina M. ;

Soulen, Michael C. ;

McGarvey, Maureen ;

Nelson, Anne Marie ;

Gladney, Whitney L. ;

Levine, Bruce L. ;

Melenhorst, J. Joseph ;

Plesa, Gabriela ;

June, Carl H. .

GASTROENTEROLOGY, 2018, 155 (01) :29-32

[10] TALEN-mediated editing of endogenous T-cell receptors facilitates efficient reprogramming of T lymphocytes by lentiviral gene transfer [J].

Berdien, B. ;

Mock, U. ;

Atanackovic, D. ;

Fehse, B. .

GENE THERAPY, 2014, 21 (06) :539-548

← 1 2 3 4 5 6 7 8 9 10 →